Number of cases and crude incidence rate (IR) per 100 000 for myeloid malignancies diagnosed in 2000-2002 archived in 44 European CRs by sex and morphologic type
| HAEMACARE groupings . | ICD-O-3 code . | ICD-O-3 description . | No. of cases . | Total . | Males . | Females . | |||
|---|---|---|---|---|---|---|---|---|---|
| IR . | 95% CI . | IR . | 95% CI . | IR . | 95% CI . | ||||
| Acute myeloid leukemia* | 8107 | 3.62 | (3.54-3.70) | 3.90 | (3.78-4.02) | 3.35 | (3.25-3.46) | ||
| Subgroup 1 | 9840 | Acute erythroid leukemia | 7545 | 3.37 | (3.29-3.45) | 3.64 | (3.53-3.76) | 3.11 | (3.01-3.21) |
| 9861 | AML, NOS | ||||||||
| 9867 | Acute myelomonocytic leukemia | ||||||||
| 9870 | Acute basophilic leukemia | ||||||||
| 9872 | AML, minimal differentiation | ||||||||
| 9873 | AML without maturation | ||||||||
| 9874 | AML with maturation | ||||||||
| 9891 | Acute monocytic leukemia | ||||||||
| 9910 | Acute megakaryoblastic leukemia | ||||||||
| 9930 | Myeloid sarcoma | ||||||||
| Subgroup 2 | 9866 | Acute promyelocytic leukemia t(15; 17) (q22; q11-12) | 311 | 0.14 | (0.12-0.16) | 0.13 | (0.11-0.15) | 0.15 | (0.13-0.17) |
| 9871 | AML with abnormal marrow eosinophils | ||||||||
| 9896 | AML, t(8,21) (q22,q22) | ||||||||
| 9897 | AML, 11q23 abnormalities | ||||||||
| Subgroup 3 | 9895 | AML, with multilineage dysplasia | 137 | 0.06 | (0.05-0.07) | 0.07 | (0.06-0.09) | 0.05 | (0.04-0.07) |
| 9984 | Refractory anemia with excess blasts in transformation (obsolete) | ||||||||
| Subgroup 4 | 9931 | Acute panmyelosis with myelofibrosis | 106 | 0.05 | (0.04-0.06) | 0.05 | (0.04-0.07) | 0.04 | (0.03-0.05) |
| Myeloproliferative neoplasms | 7474 | 3.34 | (3.26-3.41) | 3.50 | (3.39-3.62) | 3.18 | (3.08-3.28) | ||
| CML | 9863 | CML, NOS | 2468 | 1.10 | (1.06-1.15) | 1.23 | (1.17-1.30) | 0.98 | (0.92-1.04) |
| 9875 | Chronic myelogenous leukemia, BCR/ABL positive | ||||||||
| Other myeloproliferative neoplasms† | 5006 | 2.24 | (2.17-2.30) | 2.27 | (2.19-2.36) | 2.20 | (2.11-2.29) | ||
| Subgroup 1 | 9950 | Polycythemia vera | 3431 | 1.53 | (1.48-1.58) | 1.57 | (1.49-1.64) | 1.50 | (1.43-1.57) |
| 9961 | Myelosclerosis with myeloid metaplasia | ||||||||
| 9962 | Essential thrombocythemia | ||||||||
| 9963 | Chronic neutrophilic leukemia | ||||||||
| 9964 | Hypereosinophilic syndrome | ||||||||
| Subgroup 2 | 9960 | Chronic myeloproliferative disease, NOS | 1546 | 0.69 | (0.66-0.73) | 0.69 | (0.64-0.74) | 0.69 | (0.64-0.74) |
| Myelodysplastic syndrome | 4074 | 1.82 | (1.76-1.88) | 2.03 | (1.95-2.12) | 1.62 | (1.54-1.69) | ||
| 9980 | Refractory anemia | ||||||||
| 9982 | Refractory anemia with sideroblasts | ||||||||
| 9983 | Refractory anemia with excess blasts | ||||||||
| 9985 | Refractory cytopenia with multilineage dysplasia | ||||||||
| 9986 | Myelodysplastic syndrome 5q deletion | ||||||||
| 9989 | Myelodysplastic syndrome, NOS | ||||||||
| Myelodysplastic/myeloproliferative neoplasms | 776 | 0.35 | (0.32-0.37) | 0.42 | (0.38-0.46) | 0.28 | (0.25-0.31) | ||
| 9945 | Chronic myelomonocytic leukemia | ||||||||
| 9876 | Atypical CML, BCR/ABL-1 negative | ||||||||
| 9946 | Juvenile myelomonocytic leukemia | ||||||||
| 9975 | Myelodysplastic/myeloproliferative neoplasm, unclassifiable | ||||||||
| Unknown myeloid neoplasms | 1365 | 0.61 | (0.58-0.64) | 0.66 | (0.61-0.71) | 0.56 | (0.52-0.61) | ||
| Leukemia, NOS | 9800 | Leukemia, NOS | 1010 | 0.45 | (0.42-0.48) | 0.48 | (0.44-0.53) | 0.42 | (0.38-0.46) |
| 9801 | Acute leukemia, NOS | ||||||||
| 9805 | Acute leukemia, ambiguous lineage | ||||||||
| Myeloid leukemia, NOS | 9860 | Myeloid leukemia, NOS | 355 | 0.16 | (0.14-0.18) | 0.17 | (0.15-0.20) | 0.14 | (0.12-0.17) |
| All myeloid malignancies | 21 796 | 9.73 | (9.60-9.86) | 10.51 | (10.32-10.70) | 8.99 | (8.82-9.17) | ||
| HAEMACARE groupings . | ICD-O-3 code . | ICD-O-3 description . | No. of cases . | Total . | Males . | Females . | |||
|---|---|---|---|---|---|---|---|---|---|
| IR . | 95% CI . | IR . | 95% CI . | IR . | 95% CI . | ||||
| Acute myeloid leukemia* | 8107 | 3.62 | (3.54-3.70) | 3.90 | (3.78-4.02) | 3.35 | (3.25-3.46) | ||
| Subgroup 1 | 9840 | Acute erythroid leukemia | 7545 | 3.37 | (3.29-3.45) | 3.64 | (3.53-3.76) | 3.11 | (3.01-3.21) |
| 9861 | AML, NOS | ||||||||
| 9867 | Acute myelomonocytic leukemia | ||||||||
| 9870 | Acute basophilic leukemia | ||||||||
| 9872 | AML, minimal differentiation | ||||||||
| 9873 | AML without maturation | ||||||||
| 9874 | AML with maturation | ||||||||
| 9891 | Acute monocytic leukemia | ||||||||
| 9910 | Acute megakaryoblastic leukemia | ||||||||
| 9930 | Myeloid sarcoma | ||||||||
| Subgroup 2 | 9866 | Acute promyelocytic leukemia t(15; 17) (q22; q11-12) | 311 | 0.14 | (0.12-0.16) | 0.13 | (0.11-0.15) | 0.15 | (0.13-0.17) |
| 9871 | AML with abnormal marrow eosinophils | ||||||||
| 9896 | AML, t(8,21) (q22,q22) | ||||||||
| 9897 | AML, 11q23 abnormalities | ||||||||
| Subgroup 3 | 9895 | AML, with multilineage dysplasia | 137 | 0.06 | (0.05-0.07) | 0.07 | (0.06-0.09) | 0.05 | (0.04-0.07) |
| 9984 | Refractory anemia with excess blasts in transformation (obsolete) | ||||||||
| Subgroup 4 | 9931 | Acute panmyelosis with myelofibrosis | 106 | 0.05 | (0.04-0.06) | 0.05 | (0.04-0.07) | 0.04 | (0.03-0.05) |
| Myeloproliferative neoplasms | 7474 | 3.34 | (3.26-3.41) | 3.50 | (3.39-3.62) | 3.18 | (3.08-3.28) | ||
| CML | 9863 | CML, NOS | 2468 | 1.10 | (1.06-1.15) | 1.23 | (1.17-1.30) | 0.98 | (0.92-1.04) |
| 9875 | Chronic myelogenous leukemia, BCR/ABL positive | ||||||||
| Other myeloproliferative neoplasms† | 5006 | 2.24 | (2.17-2.30) | 2.27 | (2.19-2.36) | 2.20 | (2.11-2.29) | ||
| Subgroup 1 | 9950 | Polycythemia vera | 3431 | 1.53 | (1.48-1.58) | 1.57 | (1.49-1.64) | 1.50 | (1.43-1.57) |
| 9961 | Myelosclerosis with myeloid metaplasia | ||||||||
| 9962 | Essential thrombocythemia | ||||||||
| 9963 | Chronic neutrophilic leukemia | ||||||||
| 9964 | Hypereosinophilic syndrome | ||||||||
| Subgroup 2 | 9960 | Chronic myeloproliferative disease, NOS | 1546 | 0.69 | (0.66-0.73) | 0.69 | (0.64-0.74) | 0.69 | (0.64-0.74) |
| Myelodysplastic syndrome | 4074 | 1.82 | (1.76-1.88) | 2.03 | (1.95-2.12) | 1.62 | (1.54-1.69) | ||
| 9980 | Refractory anemia | ||||||||
| 9982 | Refractory anemia with sideroblasts | ||||||||
| 9983 | Refractory anemia with excess blasts | ||||||||
| 9985 | Refractory cytopenia with multilineage dysplasia | ||||||||
| 9986 | Myelodysplastic syndrome 5q deletion | ||||||||
| 9989 | Myelodysplastic syndrome, NOS | ||||||||
| Myelodysplastic/myeloproliferative neoplasms | 776 | 0.35 | (0.32-0.37) | 0.42 | (0.38-0.46) | 0.28 | (0.25-0.31) | ||
| 9945 | Chronic myelomonocytic leukemia | ||||||||
| 9876 | Atypical CML, BCR/ABL-1 negative | ||||||||
| 9946 | Juvenile myelomonocytic leukemia | ||||||||
| 9975 | Myelodysplastic/myeloproliferative neoplasm, unclassifiable | ||||||||
| Unknown myeloid neoplasms | 1365 | 0.61 | (0.58-0.64) | 0.66 | (0.61-0.71) | 0.56 | (0.52-0.61) | ||
| Leukemia, NOS | 9800 | Leukemia, NOS | 1010 | 0.45 | (0.42-0.48) | 0.48 | (0.44-0.53) | 0.42 | (0.38-0.46) |
| 9801 | Acute leukemia, NOS | ||||||||
| 9805 | Acute leukemia, ambiguous lineage | ||||||||
| Myeloid leukemia, NOS | 9860 | Myeloid leukemia, NOS | 355 | 0.16 | (0.14-0.18) | 0.17 | (0.15-0.20) | 0.14 | (0.12-0.17) |
| All myeloid malignancies | 21 796 | 9.73 | (9.60-9.86) | 10.51 | (10.32-10.70) | 8.99 | (8.82-9.17) | ||
Eight cases of therapy-related AML, NOS, and therapy-related myelodysplastic syndrome, NOS (ICD-O-3 codes 9920 and 9987, respectively) not shown in Table 3 were included with acute myeloid leukemia.
Twenty-nine cases of mastocytoma NOS/mast cell sarcoma, malignant mastocytosis, and mast cell leukemia (ICD-O-3 codes 9740, 9741, and 9742, respectively) not shown in Table 3 were included with other myeloproliferative neoplasms.